<?php include "includes/header.php" ?>

<div class="card" style="background-color: #007b9c; width: 100%; color: white; border-radius: 0; margin-top: 0%; position: absolute; border-bottom: 3px solid #004e63;" id="page-title-1">
	  <div class="card-body" style="font-weight: bold; font-size: 1.5em;">
	    Doctors
	  </div>
	</div>

	<section class="header-img" style="width: 100%;">
  
    
     	<img src="./img/patient.jpg" alt="family" id="header-1" style="width: 100%;">
        
        
</section>
<div class="content">
<div class="genericCard">
	<h3>A Doctor's Cause</h3>
	<br>
	Thank you to everyone on this long list of contributors for their continued efforts in the advancement in Neuroblastoma research. 
</div>

<div class="genericCard2">
	Dr. Giselle Sholler, Helen DeVos Hospital/NMTRC<br>
	-Targeting COMT in neuroblastoma with Tolcapone
	<br><br>
	Dr. Jason Shohet, Baylor College of Medicine<br>
	-Single cell RNA-sequencing of Neuroblastoma Cancer stem Cells:
	A piolot study to define sensitivity to epigenetic inhibitors.
	<br><br>
	University of Chicago/Comer Children's Hospital<br>
	-Family support for children going through MIBG treatment
	<br><br>
	University of Chicago -International Database Support
	<br><br>
	-Phase I/II study of PF-06463922 inhibitor of ALK/ROS1 for patients
	with ALK driven relapsed or refactory neuroblastoma
	<br><br>
	-General Support & Research
	<br><br>
	Dr. Ting Tao: Dana Farber Cancer Institute <br>
	-The Role of ARID1A in neuroblastoma tumorigenesis
	<br><br>
	Dr. Bilal Omer:  Baylor College of Medicine <br>
	-Improving immune cell trafficking to neuroblastoma with “scout cells
	<br><br>
	Dr. Jason Shohet:  Baylor College of Medicine <br>
	-Analysis of p53 responses and regulation by G-CSFin neuroblastoma cancer stem cell subpopulations.
	<br><br>
	Dr. Julie Park:  Seattle Children’s Hospital <br>
	-MIBG Scoring Project: COGA3973 and SIOPEN-NBL-1
	<br><br>
	Dr. Sam Volchenboum: Comer Children’s Hospital <br>
	-“The MYCN Oncogene: Providing Insight to Improved Diagnostic Stratification,
	Therapeutic Evaluation, and Novel Treatment Design for High-Risk Neuroblastoma.”
	<br><br>
	SIOPEN
	<br><br>      
	-Travel grant for MIBG Scoring Project <br>
	MIBG Scoring Project: COGA3973 and SIOPEN-NBL-1
	<br><br>
	Dr. Eveline Barbieri. Baylor College of Medicine <br>
	-A novel therapeutic approach to p53 wild type Neuroblastoma: Sestrin <br>
	2 mediated inhibition of the PI3K/AKT/mTOR pathway
	<br><br>
	Dr. Qiwei Yang, University of Illinois, Chicago <br>
	-DNMT3B7-mediated epigenetic alteration and anti-tumorigenic effect in neuroblastoma
	<br><br>
	Dr. Yibing Xu, Children’s Hospital Los Angeles <br>
	-Natural Killer Cell Based Immunotherapy of Neuroblastoma
	<br><br>
	Dr. Susan Cohn, University of Chicago <br>
	-Interactive International Neuroblastoma Information Network
	<br><br>
	Dr. Susan Cohn, University of Chicago <br>
	-Genome-wide Analysis of Favorable Stage Neuroblastoma with MYCN Amplification
	<br><br>
	Dr. Nai-Kong Cheung, Memorial Sloan Kettering <br>
	-Humanized 3F8 Research
	<br><br>
	Dr. Heidi Russell, Texas Children’s Hospital <br>
	-Pepi Trial
	<br><br>
	Metin Gurcan PhD, Ohio State University <br>
	-Computer aided prognosis of Neuroblastoma
	<br><br>
	Dr. Kelly Goldsmith, Children’s Hospital of Philadelphia <br>
	-Polymine Depletion Strategies in Neuroblastoma
	<br><br>
	Dr. Eugene Kim, Baylor College of Medicine <br>
	-The Role of MDM2 in Tumor Angiogenesis in Neuroblastoma
	<br><br>
	Dr. Hong Xu, Memorial Sloan Kettering <br>
	-B7H3: An Immunological Target for Neuroblastoma
	<br><br>
	Dr. Barry Mauerer, Texas Tech University <br>
	Purchase of Fenretinide
	<br><br>
	Drs. Seeger/Reynolds, Children’s Hospital LA <br>
	-Private donation
	<br><br>
	Dr. Susan Cohn, University of Chicago - Genome Wide
	<br><br>
	Dr. Cynthia van Golen, Delaware State University <br>
	-Therapeutic Efficacy of Agents Targeting the IGF-IR in Human Neuroblastoma
	<br><br>
	Dr. Elizabeth Beierle, University of Florida/ <br>
	University of Alabama, Birmingham <br>
	-Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor-3 in Neuroblastoma
	<br><br>
	Dr. Tasnim Ara, Children’s Hospital Los Angeles <br>
	-Contribution of Bone Marrow Microenvironment to Neuroblastoma Chemoresistance and Tumor Progression
	<br><br>
	Dr. Alexandre Chlenski, University of Chicago <br>
	-SPARC-derived peptides for the treatment of Neuroblastoma
	<br><br>
	Dr. Kristina Cole, Children’s Hospital of Philadelphia <br>
	-siRNA Inhibition of the Protein Kinome in Neuroblastoma
	<br><br>
	Dr. Nai-Kong Cheung, Memorial Sloan Kettering <br>
	<br><br>
	Sonia Hernandez, Columbia University <br>
	-Notch Signaling Pathway and VEGF Blockade in Neuroblastoma
	<br><br>
	Dr. Jason Shohet, Baylor College of Medicine <br>
	-MYCN-regulated MicroRNA Expression in Neuroblastoma
	<br><br>
	Drs. Seeger/Reynolds, Children’s Hospital of Los Angeles <br>
	-Private donation
	<br>
	Dr. Edward Attiyeh, Children’s Hospital of Philadelphia <br>
	-Genetic basis of aggressive neuroblastoma
	<br><br>
	Dr. Louis Chesler, University of CA, San Francisco <br>
	-Proteomic analysis of serum from children with neuroblastoma  
	<br><br>
	Dr. Radoslaw Zagoadzon, Beth Israel Deaconess <br>
	-Studies on the role of CHK Kinase on Neuroblastoma
</div>
</div>

<?php include("includes/footer.php") ?>